A Study of Imaging in Demyelinating Diseases

Overview

Información sobre este estudio

The purpose of this study is to investigate white matter myelin integrity using Pittsburgh compound-B positron emission tomography (PiB PET) imaging in patients in different phases of MS and related disorders. Also, to measure neuroinflammation and microglial activity using translocator protein 18 (TSPO) PET imaging in different phases of MS and related disorders. In addition, to determine if white matter integrity and neuroinflammation measured by PET imaging, are associated with disease course, clinical disability accumulation and other imaging markers of disease burden in MRI, MR spectroscopy MRS and DTI.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Males or females 18 years of age or older.
  • Meet the requirements for one of the case or control groups.
  • MS patients undergoing neurologic evaluation procedures as part of Understanding Sex Differences in Multiple Sclerosis Spectrum of Demyelinating Disorders (IRB# 19-002807) Study or the Mayo Clinic Neurology Multiple Sclerosis Clinic
  • Control group (n=100) without inflammatory-demyelinating diseases of the central nervous system (Control group (n=100) will have no MS or related disorder diagnosis).
  • Capacity to sign consent

Exclusion Criteria:

  • Participants unable to lie down without moving for 20 minutes.
  • Women who are pregnant or cannot stop breast feeding for 24 hours.
  • For all patients and controls, any acute glucocorticoid (e.g. IV methylprednisolone or PO prednisolone) use within 2 weeks is an exclusion to limit medication interaction but preserve possible chronic systemic inflammation interaction with microglia activation metrics. Chronic disease modifying treatments in MS are allowed as these medications are not known to impact microglia activation.
  • Standard safety exclusionary criteria for MRI such as metallic foreign bodies, pacemaker, etc., since the quantitative PET data analysis is based on anatomic criteria that are established uniquely for each subject by registration to his/her MRI.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 9/27/23. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Burcu Zeydan, M.D.

Abierto para la inscripción

Contact information:

June Kendall Thomas

KendallThomas.June15@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20547008

Mayo Clinic Footer